首页 > 市场调查报告书 > 医疗设备

医学影像诊断生技设备

市场调查报告书

商品编码

1542918

全球生物成像技术市场 - 2024-2031

Global Bio Imaging Technologies Market - 2024-2031

出版日期: 2024年08月26日 | 出版商:

DataM Intelligence | 英文 200 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

生物成像技术市场规模

全球生物成像技术市场2023年达到59.4亿美元，预计到2031年将达到176亿美元，2024-2031年预测期间复合年增长率为15.3%。

生物成像技术是提供生物製程非侵入性可视化的方法。多种技术可用于成像目的。这些技术尽可能减少对生命过程的干扰，并在没有任何物理干扰的情况下提供样本 3D 结构的资料。

生物成像技术市场动态

推动全球生物成像技术市场的主要因素是慢性疾病的增加、研发和临床试验的增加以及技术的进步。新颖产品推出的增加有助于生物成像技术市场的成长。

研发投资的增加和进步以及新颖产品的推出预计将推动市场的成长。

这些生物影像技术产品越来越多地用于诊断、预防或治疗各种慢性疾病（例如神经退化性疾病和癌症），以及不断增加的新产品发布推动了生物成像技术市场。癌症发生率的增加也有助于市场成长。许多医疗保健公司增加了研发活动来开发新产品。

生物影像技术用于各种疾病的诊断、预防或治疗目的。由于案例数量不断增加，这些技术的应用市场在全球范围内不断扩大。此外，主要参与者提供技术先进的产品预计也将在市场的成长中发挥至关重要的作用。

各种新产品的推出、监管部门的批准和研究都有助于市场的成长。例如，2022 年 8 月 3 日，雅培宣布其由 Ultreon Software 支援的新型光学相干断层扫描成像平台 (OCT) 已获得美国食品药物管理局的批准。这是一款创新的影像软体，将人工智慧（AI）与OCT相结合，为医生提供高而全面的冠状动脉血流量和遮挡视野，以协助他们决策并提供最佳治疗途径。

生物成像技术的高成本预计将阻碍市场的成长。

然而，这些生物成像技术的高成本是限制市场成长的主要因素。其他限制包括高辐射剂量输送，长期来看可能导致遗传性疾病。

通常将辐射剂量调整为所需的目标辐射，但仍可能诱发癌症。探针和染料的添加会干扰脂质囊泡的特性，并可能导致实验假象，导致资料解释不准确。

COVID-19 对生物影像技术市场的影响

疫情对全球金融预期、营运和危机应对策略产生了积极影响。 COVID-19 的爆发严重影响了医疗保健产业。由于新冠肺炎，生物成像技术市场获得了巨额利润，因为各种研究和诊断中心开始启动，并且由于新冠病例及其诊断的不断增加，对这些技术的需求也随之增加。全球正在发生多项措施、产品发布、创新、合作和合併，推动了市场的成长。例如，2022 年6 月14 日，迈瑞宣布在2022 年欧洲麻醉展上推出其新型TEX20 系列超音波系统。的资讯解决方案、智慧工具和以临床为导向的工作流程，经过深思熟虑的设计。

生物成像技术市场細項分析

奈米生物成像领域预计在预测期内（2024-2031）将以最快的复合年增长率成长

奈米生物成像领域是全球生物成像技术市场中最大的市场占有者。全球生物成像技术市场根据技术类型进行细分：奈米生物成像、光学成像、正电子发射断层扫描、磁振造影、超音波成像、电脑断层扫描、放射成像等。奈米生物成像领域因其更好的功效和结果、优于其他技术的优势以及这些生物成像技术的不断进步和采用而成为最大的市场份额。

奈米技术可以解决高解析度影像建构的障碍。奈米技术可以将正子断层扫描技术的进步提升到一个新的水平，因为它可以最大限度地提高目前可用技术的分辨率。奈米生物成像可以藉助独特设计的奈米结构来提高目标成像特异性。在医学和萤光生物成像研究中，奈米材料的增强作用反映了奈米技术对生物成像的影响。最重要的是，奈米生物成像技术或成像与奈米粒子的组合提供了改进的对比影像。各种生物相容性奈米晶体和小分子造影剂可以提供强大的成像讯号。

越来越多的监管批准、技术进步、产品发布和研究/临床试验研究推动了市场的成长。例如，2022 年9 月12 日，Clario 探索了神经影像或神经黑色素MRI 和Opal 感测器技术的益处，因为它提高了临床结果测量的精度和质量，因此在帕金森氏症国际大会上描述了分散临床试验的数字终点疾病和运动障碍 2022。

生物成像技术市场地域份额

北美在全球生物成像技术市场中占有最大的市场份额。

北美在全球生物成像技术市场占据主导地位，这主要是由于其人口众多、医疗基础设施完善以及慢性疾病数量不断增加。根据美国癌症协会估计，到 2022 年，美国将出现约 60,650 例新的白血病病例，其中 24,000 例死亡。 65 岁或以上的人中，约有九分之一患有痴呆症；到 2050 年，这一数字预计将达到 1,270 万人左右。越来越多的大脑健康问题、心血管疾病和癌症病例增加了对生物成像技术的需求。

医疗保健支出的增加和人们意识的提高也促进了该地区市场的成长。生物影像技术在多种疾病诊断和检查中的应用取得进展，为进一步研究提供人体生理学资料库，区域内製药机构和政府审批的增加，以及该领域关键参与者的存在该地区正在为生物成像技术市场的成长做出贡献。

此外，产品发布数量的增加也是市场成长的原因。该地区正在发生许多重要的发展、监管批准、技术进步、合作和协议。例如，2021 年 5 月 28 日，医疗设备和解决方案开发商和提供者迈瑞推出了新型普通影像、心臟病和女性医疗保健超音波解决方案。其开发目的是为了提高诊断证据的强度，以确保改善患者护理。

生物成像技术市场公司及竞争格局

生物成像技术市场与本地和全球公司的竞争非常激烈。 GE Healthcare、Abbott Laboratories、Hitachi Medical Corporation、Bayer AG、Esaote SpA、Clario、Digirad Corporation、Bracco、深圳迈瑞生物医疗电子有限公司、Hologic Inc.、FONAR Corporation 等。主要参与者正在采取各种成长策略，例如产品发布、併购、合作伙伴关係和协作，为市场的成长做出贡献。例如，2021 年 3 月 31 日，MR 扫描投资者 FONAR Corporation 宣布收购纽约州扬克斯市的一家站立式 MRI 设施，FONAR 的诊断影像管理子公司 Health Management Company of America 将从该设施提供非纽约MRI医疗管理服务。

通用电气医疗保健。

概述：GE医疗保健是通用电气的子公司，通用电气是一家融入纽约的美国跨国企业集团，成立于1994年，总部位于伊利诺州芝加哥。它生产和分销各种诊断成像剂和放射性药物，可用于某些程序（例如医学成像）中的成像方式。

产品组合：

SIGNA MR：Signa 是一款 MR 产品，透过高效的生产力和扫描工作流程解决方案增强了磁振造影的功能，并为先进的临床程序提供了创新。

主要进展：2022 年 10 月，GE Healthcare 在欧洲核子医学会年度会议上推出了 Omni Legend。该系统首次出现在其全新的数位 PET/CT 平台上，因为它采用最新的晶体尺寸数位 BGO 探测器材料类别，能够提供比以前的数位扫描仪高两倍的灵敏度。

全球生物成像技术市场报告将提供约：45 个以上的市场资料表、40 个以上的图表和 200 个（大约）页数。

Bio-imaging technologies are the methods that provide non-invasive visualization of biological processes. Several technologies can be used for imaging purposes. These technologies interfere with the life processes as minimally as possible and provide data on the 3D structure of the sample without any physical interference.

Bio-Imaging Technologies Market Dynamics

The major factors driving the global bio-imaging technologies market are increased chronic disorders, rising research and development and clinical trials, and technological advancements. An increase in novel product launches contributes to the growth of the bio-imaging technologies market.

The increasing investment and advancements in R&D and rising novel product launches are expected to drive the market's growth.

The rising adoption of these bio-imaging technologies products for the diagnosis, prevention, or treatment of various chronic disorders, such as neurodegenerative disorders and cancer, and the rising number of novel product launches drive the bio-imaging technologies market. An increase in the incidence of carcinomas is also aiding market growth. There has been an increase in R&D activities by many healthcare companies to develop novel products.

Bio-imaging technologies are used in various diseases for diagnostic, preventive, or treatment purposes. The market for the applications of these technologies is increasing worldwide due to the increasing number of cases. Moreover, the availability of technologically advanced products by key players is also expected to play a vital role in the market's growth.

Various novel product launches, regulatory approvals, and research studies contribute to the market's growth. For instance, in August 3, 2022, Abbott announced that its novel optical coherence tomography imaging platform (OCT), Ultreon Software powered, had received clearance from the U.S. Food and Drugs Administration. This is an innovative imaging software that combines artificial intelligence (AI) with OCT to provide high and comprehensive coronary blood flow, and blockages view to physicians to assist their decision-making and offer the best pathway of treatment.

The high cost associated with bio-imaging technologies is expected to hamper the market's growth.

However, the high cost of these bio-imaging technologies is the leading factor restraining the market's growth. Other limitations include high radiation dose delivery that can lead to genetic disorders in the long term.

The radiation dose is generally adjusted at the desired target radiation but can still induce cancer. The probes and dye addition interferes with lipid vesicle properties and can cause experimental artifacts that result in an inaccurate interpretation of data.

COVID-19 Impact on Bio-Imaging Technologies Market

The pandemic has positively impacted global financial expectations, operations, and crisis response strategy. The COVID-19 outbreak has severely affected the healthcare industry. The bio-imaging technologies market has experienced huge profits due to COVID, as various research and diagnostic centers started and demand for these technologies rose due to the increasing cases of COVID and its diagnosis. Multiple initiatives, product launches, innovations, collaborations, and mergers are happening worldwide, boosting the market's growth. For instance, in June 14, 2022, Mindray announced the launch of its novel TEX20 Series ultrasound system at the Euroanaesthesia 2022. This system has improved features than its predecessors as it provides high image clarity, patient-centered information solution, intelligent tools, and clinical-oriented workflow with thoughtful design.

Bio-Imaging Technologies Market Segment Analysis

The nano bio-imaging segment is expected to grow at the fastest CAGR during the forecast period (2024-2031)

The nano bio-imaging segment is the highest market holder in the global bio-imaging technologies market. The global bio-imaging technologies market is segmented based on technology type: nano bio-imaging, optical imaging, Positron Emission Tomography, magnetic resonance imaging, ultrasound imaging, computed tomography, radiological imaging, and others. The nano bio-imaging segment is the largest market shareholder due to its better efficacy and results, advantages over other technologies, and rising advancements and adoption of these bio-imaging technologies.

Nanotechnology can solve the high-resolution image construction barrier. Nanotechnology can take Positron Emission Tomography advancements to the next level as it can maximize the resolution in currently available techniques. Nano bio-imaging can increase the target imaging specificity with the help of uniquely designed nano constructs. In medical and Fluorescence Bioimaging research, the enhanced role of nanomaterials reflects nanotechnology's impact in bioimaging. The nano bio-imaging technique or combination of imaging and nanoparticle, most importantly, provides improved contrast images. Various biocompatible nanocrystals and small molecule contrast agents can offer strong imaging signals.

The growing number of regulatory approvals, technological advancements, product launches, and research/clinical trial studies drive the market's growth. For instance, in September 12, 2022, Clario explored neuroimaging or neuromelanin MRI and Opal sensor tech can be beneficial as it improves the precision and quality of the clinical outcome measures hence, characterizing the digital endpoints for decentralized clinical trials at the International Congress of Parkinson's Disease and Movement Disorders 2022.

Bio-Imaging Technologies Market Geographical Share

North America holds the largest market share in the global bio-imaging technologies market.

North America dominates the global bio-imaging technologies market, primarily due to its large population, excellent medical infrastructure, and rising number of chronic disorders. According to the American Cancer Society, in 2022, Around 60.650 estimated novel leukemia cases will occur, out of which 24,000 deaths will appear in the United States. About 1 out of 9 people 65 years or older have dementia; by 2050, this is expected to reach around 12.7 million. The increasing number of brain health issues, cardiovascular disorders, and cancer cases boost the demand for bio-imaging technologies.

Increasing expenditure on healthcare and raising awareness among people are also contributing to the market's growth in this region. Advancement of applications of bio-imaging technologies in the diagnosis and examination of several diseases, providing the database of the physiology of the human body for further studies, increase in pharmaceutical establishment across the region and government approvals, and the presence of key players in the region are contributing to the growth of the Bio-Imaging Technologies market.

Moreover, the growing number of product launches is responsible for the market's growth. Many vital developments, regulatory approvals, technological advancements, collaborations, and agreements are taking place in this region. For instance, in May 28, 2021, Mindray, medical devices and solutions developer and provider, launched its novel general imaging, cardiology, and women's healthcare ultrasound solutions. This is developed to increase the diagnostic evidence strength for ensuring improved patient care.

Bio-Imaging Technologies Market Companies and Competitive Landscape

The bio-imaging technologies market is highly competitive with local and global companies' presence. GE Healthcare, Abbott Laboratories, Hitachi Medical Corporation, Bayer AG, Esaote S.p.A, Clario, Digirad Corporation, Bracco, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Hologic Inc., FONAR Corporation, and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in March 31, 2021, FONAR Corporation, an MR Scanning investor, announced its acquisition of a Yonkers, New York-based Stand-Up MRI facility from where Health Management Company of America, FONAR's diagnostic imaging management subsidiary will offer non-medical management services for MRI of New York.

GE Healthcare.

Overview: GE HealthCare is a subsidiary of General Electric, an American multinational conglomerate integrated into New York, founded in 1994 and headquartered in Chicago, Illinois. It manufactures and distributes various diagnostic imaging agents and radiopharmaceuticals that can be used for imaging modalities in some procedures, such as medical imaging.

Product Portfolio:

SIGNA MR: Signa is the MR product that increases the capabilities of magnetic resonance imaging with efficient productivity and workflow solutions for scanning and offers innovations to advanced clinical procedures.

Key Developments: In Oct 2022, GE Healthcare introduced Omni Legend at the annual European Nuclear Medicine Associations meeting. This system is first on its all-novel and digital PET/CT platform as it features the latest, crystal-size digital BGO detector material category capable of providing two times more sensitivity than prior digital scanners.

The global bio-imaging technologies market report would provide access to approx.: 45+ market data tables, 40+ figures, and 200 (approximate) pages.

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

4.1. Market Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increasing number of clinical trials
  - 4.1.1.2. Rising technological advancements
- 4.1.2. Restraints:
  - 4.1.2.1. High cost of bio-imaging
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis

6. COVID-19 Analysis

6.1. Analysis of Covid-19 on the Market
- 6.1.1. Before COVID-19 Market Scenario
- 6.1.2. Present COVID-19 Market Scenario
- 6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturer's Strategic Initiatives
6.6. Conclusion

7. By Technology Type

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
- 7.1.2. Market Attractiveness Index, By Technology Type
7.2. Nano-Bio Imaging *
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.3. Optical Imaging
7.4. Positron Emission Tomography
7.5. Magnetic Resonance Imaging
7.6. Ultrasound Imaging
7.7. Computed Tomography
7.8. Radiological Imaging
7.9. Fluorescence Bioimaging
7.10. Others

8. By Application

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 8.1.2. Market Attractiveness Index, By Application
8.2. Medical Bio-Imaging *
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.3. Molecular Bio-Imaging

9. By End-User

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.1.2. Market Attractiveness Index, By End-User
9.2. Hospitals *
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
9.3. Diagnostic Centers
9.4. Others

10. By Region

10.1. Introduction
- 10.1.1. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
- 10.1.2. Market Attractiveness Index, By Region
10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
- 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.2.6.1. U.S.
  - 10.2.6.2. Canada
  - 10.2.6.3. Mexico
10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
- 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.3.6.1. Germany
  - 10.3.6.2. U.K.
  - 10.3.6.3. France
  - 10.3.6.4. Italy
  - 10.3.6.5. Spain
  - 10.3.6.6. Rest of Europe
10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.4.6.1. Brazil
  - 10.4.6.2. Argentina
  - 10.4.6.3. Rest of South America
10.5. Asia Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.5.6.1. China
  - 10.5.6.2. India
  - 10.5.6.3. Japan
  - 10.5.6.4. Australia
  - 10.5.6.5. Rest of Asia Pacific
10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
- 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

11.1. Key Developments and Strategies
11.2. Company Share Analysis
11.3. Products Benchmarking
11.4. List of Key Companies to Watch

12. Company Profiles

12.1. GE Healthcare *
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio and Description
- 12.1.3. Key Highlights
- 12.1.4. Financial Overview
12.2. Abbott Laboratories
12.3. Hitachi Medical Corporation
12.4. Bayer AG
12.5. Esaote S.p.A
12.6. Clario
12.7. Digirad Corporation
12.8. Bracco
12.9. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
12.10. Hologic Inc.
12.11. FONAR Corporation(*LIST NOT EXHAUSTIVE)

13. DataM Intelligence

13.1. Appendix
13.2. About Us and End-User
13.3. Contact Us

02-2729-4219

+886-2-2729-4219

License/价格

全球生物成像技术市场 - 2024-2031

Global Bio Imaging Technologies Market - 2024-2031

产品组合：

目录

第 1 章：方法与范围

第 2 章：市场定义与概述

第 3 章：执行摘要

第 4 章：市场动态

第 5 章：产业分析

第 6 章：COVID-19 分析

第 7 章：按技术类型

第 8 章：按申请

第 9 章：最终用户

第 10 章：按地区

第 11 章：竞争格局

第 12 章：公司简介

第 13 章：数据M